Table 2. Univariate analysis for the association between clinical characteristics with survival in advanced pancreatic cancer patients.
| HR | 95%CI | P value | |
|---|---|---|---|
| Gender | |||
| Male | 1 | ||
| Female | 0.617 | 0.420-0.907 | 0.018 |
| Age | |||
| ≤57 | 1 | ||
| >57 | 1.044 | 0.615-1.774 | 0.873 |
| KPS | |||
| 90 | 1 | ||
| 70-80 | 2.376 | 0.868-6.499 | 0.092 |
| Pathological differention | |||
| Well-moderate | 1 | ||
| Poor | 1.132 | 0.954-1.343 | 0.043 |
| Location | |||
| Head | 1 | ||
| Body/tail | 1.013 | 0.694-1.480 | 0.946 |
| Disease extension | |||
| Distant metastasis | 1 | ||
| Locally advanced | 0.693 | 0.447-1.074 | 0.101 |
| First-line chemotherapeutic regimens | |||
| Gemcitabine monotherapy | 1 | ||
| Gemcitabine and S-1/capecitabine | 0.783 | 0.450-1.363 | 0.387 |
| Gemcitabine and platinum drugs | 0.522 | 0.219-1.244 | 0.142 |
| Gemcitabine and nab-paclitaxel | 0.601 | 0.397-0.910 | 0.016 |
| Second-line chemotherapy | |||
| No | 1 | ||
| Yes | 0.666 | 0.474-0.936 | 0.019 |
| Timing of CIN | |||
| Non-early | 1 | ||
| Early | 0.644 | 0.441-0.941 | 0.023 |
Abbreviation: CIN, chemotherapy-induced neutropenia;
A two-sided significance level of 0.05 was used to evaluate statistical significance.